Eosinophilic esophagitis (EoE) is associated with eosinophil and mast cell accumulation, which promotes dysphagia and esophageal dysmotility. 1, 2 Cytokines and chemokines implicated in eosinophil-, mast cell-, and basophil-mediated EoE pathogenesis include interleukin (IL)-5, IL-13, thymic stromal lymphopoietin, and eotaxin-3. [3] [4] [5] [6] A correlation between IL-5 and eotaxin-3 expression and eosinophil infiltration has been observed. 7 Nevertheless, it is not clear if eotaxin-3 is the only chemokine, or one of several, that directs eosinophil accumulation in EoE. Herein, we present evidence that a neuroimmune pathway is involved in eosinophil and mast cell accumulation and degranulation in human EoE.
Morphologically, eosinophils accumulate near nerves within the muscular mucosa of the esophagus ( Figure 1A ). This spatial association suggests that nerve cells may release chemoattractants in EoE. We hypothesize that one such chemoattractant might be vasoactive intestinal peptide (VIP), which has been implicated in eosinophil recruitment during allergic disease (eg, asthma). VIP expression was low in control esophageal biopsy specimens (ie, without eosinophils) ( Figure 1B-D) . In contrast, eosinophils accumulated adjacent to VIPexpressing nerve cells in EoE biopsy specimens ( Figure 1E-G) .
VIP performs its immunologic functions via binding to 3 receptors: vasoactive intestinal peptide receptor 1 (VPAC-1), VPAC-2, and chemoattractant receptor homologous molecule expressed on Th2 (CRTH2) lymphocytes. 8, 9 Our in vitro analyses indicated that eosinophils mainly express CRTH2 receptor, not VAPC1, VAPC2, and VIP (Supplementary Figure 1A-D) . Furthermore, eosinophil motility in response to VIP is comparable with that induced by eotaxin (Supplementary Figure 1E) , and that anti-CRTH2 pretreatment restricted human eosinophil motility (Supplementary Figure 1F) . In EoE biopsy specimens, we show that CRTH2-expressing eosinophils accumulated in the epithelial mucosa (Supplementary  Figure  2A-F) .
Furthermore, mast cell contribution to the pathogenesis of EoE also has been reported, but the mechanism of mast cell recruitment to the esophagus is undefined. Immunofluorescence analyses confirmed CRTH2 receptor on tryptase-positive mast cells in the esophageal mucosa of EoE patients (Supplementary Figure 2G- 10 However, the effect of the CRTH2 antagonist on mast cells that may be critical to the esophageal functional abnormalities observed in EoE was not examined. Therefore, to better assess the potential therapeutic utility of in vivo CRTH2 blockade, we initially assessed eosinophil and mast cell distributions in mice after induction of experimental EoE (Supplementary Figure 3) . 11 As in the human study, eosinophil infiltration in each segment of the esophagus was reduced in CRTH2 antagonist-treated mice (Figure 2A-D) . This was Taken together, the current studies identify a novel and important chemoattractant role for VIP in the accumulation of eosinophils and mast cells in the pathogenesis of EoE. Moreover, we suggest that inhibiting the VIP-CRTH2 axis may ameliorate the dysphagia, stricture, and motility dysfunction of chronic EoE. 1,2 Briefly, in formalin-fixed, paraffin-embedded sections from esophageal biopsy specimens, endogenous peroxide was quenched using 0.3% hydrogen peroxide in methanol, followed by antigen retrieval with pepsin, and blocking with 3% goat serum to reduce the nonspecific binding. Esophageal eosinophils were detected using rat anti-MBP (kindly provided by Dr Jamie Lee, Mayo Clinic, Scottsdale, AZ) antibody followed by Tetramethylrhodamine (TRITC)-labeled anti-rat IgG that was used as a secondary antibody. Furthermore, anti-CRTH2 antibody (ProSci) followed by fluorescein isothiocyanate-labeled anti-rabbit IgG (Biolegend, San Diego, CA) were used as a secondary antibody to detect CRTH2-receptor expression on eosinophils on esophageal biopsy specimens. VIP-expressing nerve fibers were detected using goat anti-VIP antibody followed by fluorescein isothiocyanate-anti-goat IgG antibody that were used as secondary antibodies to detect VIP-producing nerve cells. In addition, CRTH2-receptor expression on anti-human tryptase-positive (BioRad) mast cells was detected using antitryptase antibody followed by Phycoerythrin-labeled anti-mouse IgG, which was used as a secondary antibody for mast cell and anti-CRTH2 antibody (ProSci, Poway, CA), followed by fluorescein isothiocyanate-labeled anti-rabbit IgG (Biolegend, San Diego, CA) as a secondary antibody for CRTH2 expression on mast cells in esophageal biopsy specimens. The doubleimmunostained tissue sections slides were mounted with 4 0 ,6-diamidino-2-phenylindole mounting material (Thermo Fisher Scientific, Waltham, MA), and the images were captured using an Olympus-BX43F (Tokyo, Japan).
Supplementary Methods

Clinical Characteristics of EoE and non-EoE patients
Formalin-fixed, paraffin-embedded biopsy samples were obtained from the esophagus of control patients or EoE patients as per an Institutional Review Board-approved protocol. The comparison groups included control patients (non-EoE), EoE, and dysphagia patients, who were selected without regard to age, atopic status, or sex. The diagnosis was established based on the maximum eosinophil count per high-power field (Â400). Control patients (non-EoE) were defined as having 0-2 esophageal eosinophils/high-power field and no basal layer expansion.
CRTH2 Antagonist Treatment in Experimental EoE
Specific pathogen-free BALB/c mice were obtained from The Jackson Laboratory (Bar Harbor, ME). All of the experiments were performed on ageand sex-matched mice 6-8 weeks of age. The Tulane Institutional Animal Care and Use Committee approved the animal protocols. Experimental EoE in mice was induced using methods described previously [3] [4] [5] that were used in accordance with National Institutes of Health guidelines. In brief, mice were lightly anesthetized with isoflurane (Iso-Flo; Abbott Laboratories, North Chicago, IL), and 100 mg of Aspergillus fumigatus (Greer Laboratories, Lenoir, NC) in 50 mL normal saline or 50 mL normal saline alone was given intranasally using a micropipette with the mouse held in the supine position 3 times/wk for 3 weeks. In addition, 100 mg/mice CRTH2 antagonist (OC000459) (Cayman Chemical, Ann Arbor, MI) was given intravenously on an alternate day up to the last Aspergillus challenge. The mice were euthanized after 24 hours of their last intranasal allergen or saline challenge. Esophageal tissues sections were analyzed for eosinophils by anti-MBP immunostaining and for mast cells by chloroacetate esterase staining as per the earlier-described protocol. 2, 6, 7 Flow Cytometer Analysis for VIP and VIP-Receptor Expression on Blood Eosinophils VIP-, VPAC-1-, VPAC-2-, and CRTH2-receptor expression on blood eosinophils from EoE patients was tested by flow cytometric analysis as described earlier. 8, 9 The blood cells were stained with different florescence-tagged antihuman C-C motif chemokine receptor 3 (hCCR3) (Biolegend, San Diego, CA), anti-human Sialic acid-binding Ig-like lectin 8 (hSiglec-8) (Biolegend), antihVIP, anti-hVPAC-1, anti-hVPAC-2, and anti-hCRTH2 antibodies (Santa Cruz Biotechnology, Dallas, TX, and Biolegend). Depending on availability, we used both fluorescence-tagged antibodies or the combination of both primary and secondary antibodies tagged with different florescent-tagged IgG (Santa Cruz Biotechnology, Biolegend, or eBioscience, San Diego, CA). Respective labeled IgG antibodies were used as isotype control. Fluorescence-activated cell sorter analysis was performed using a FACS Calibur (BD Biosciences, San Diego, CA) and analyzed by FlowJo software (BD Biosciences).
Eosinophil Migration Assay
The chemoattractant behavior of VIP for eosinophils was analyzed in vitro using Transwell units (24 wells) with 5-mm porosity polycarbonate filters (Corning, Inc, Corning, NY) following the previously described protocol. 1 The human blood eosinophils were incubated with the anti-human CCR3 and anti-human Siglec-8 antibodies for 45 minutes, washed, and eosinophils were separated by fluorescence-activated cell sorter. The purified human eosinophils (10 5 cells/ well) in Hank's balance salt solution, pH 7.2 (Life Technologies, Carlsbad, CA) were placed in the upper chamber and different concentrations of recombinant VIP (1, 10, 100, and 500 ng/ mL) were added to the lower chamber. Eotaxin-2 (200 ng/mL), a known chemoattractant for eosinophils, was used as a positive control. The Transwell unit was kept at 37 C for 4 hours in a humidified 95% air-5% CO 2 atmosphere. After 4 hours, media from the lower chamber was centrifuged at 250 g, and cells were resuspended in phosphate-buffered saline. The number of migrated cells in the lower chamber was counted with a hemocytometer. Each assay was set up in triplicate and repeated 3 times. The data are expressed as an eosinophil migration index, which is defined as the ratio of the migration of eosinophils in the presence of the chemoattractant VIP, and the migration of eosinophils to the medium control.
Statistical Analysis
Parametric data were compared using t tests between 2 groups. Values are reported as means ± SD. P values less than .05 were considered statistically significant.
